Publications by authors named "S Trop"

Article Synopsis
  • A study was conducted to evaluate the effects of the proton-pump inhibitor pantoprazole on critically ill patients undergoing invasive ventilation, comparing it to a placebo.
  • The trial included 4,821 patients and found that pantoprazole significantly reduced the incidence of clinically important upper gastrointestinal bleeding compared to placebo (1.0% vs. 3.5%).
  • However, there was no significant difference in overall mortality rates at 90 days between the pantoprazole group (29.1%) and the placebo group (30.9%).
View Article and Find Full Text PDF

Unlabelled: Clinical research in Canada is conducted primarily in "academic" hospitals, whereas most clinical care is provided in "community" hospitals. The objective of this nested observational study was to compare patient characteristics, outcomes, process-of-care variables, and trial metrics for patients enrolled in a large randomized controlled trial who were admitted to academic and community hospitals in Canada.

Design: We conducted a preplanned observational study nested within the Probiotics: Prevention of Severe Pneumonia and Endotracheal Colonization Trial (PROSPECT, a randomized controlled trial comparing probiotics to placebo in mechanically ventilated patients) Research Program.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigates the effectiveness of probiotics, specifically Lactobacillus rhamnosus GG, in preventing ventilator-associated pneumonia (VAP) and other infections in critically ill patients in ICUs across North America and Saudi Arabia.
  • A large randomized trial involved 2,653 patients, showing no significant reduction in VAP rates among those receiving probiotics compared to the placebo group (21.9% vs. 21.3%).
  • None of the secondary outcomes, including rates of other infections or mortality, showed improvements, suggesting that probiotics may not offer substantial benefits in this patient population.
View Article and Find Full Text PDF

Introduction: Enterotoxigenic Escherichia coli (ETEC) is a common cause of infectious diarrhoea and a leading cause of morbidity and mortality in children living in resource-limited settings. It is also the leading cause of travellers' diarrhoea among civilian and military travellers. Its dual importance in global public health and travel medicine highlights the need for an effective vaccine.

View Article and Find Full Text PDF

Background: Human challenge models for enterotoxigenic Escherichia coli (ETEC) facilitate vaccine down-selection. The B7A (O148:H28 CS6+LT+ST+) strain is important for vaccine development. We sought to refine the B7A model by identifying a dose and fasting regimen consistently inducing moderate-severe diarrhea.

View Article and Find Full Text PDF